ALPHAMAB-B(09966): JSKN003 has obtained approval from the CDE to conduct a Phase III clinical study for the treatment of ovarian cancer.

ALPHAMAB-B (09966) announced that JSKN003 has received approval from the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct a Phase III clinical study (Study ID: JSKN003-306). JSKN003-306 is a randomized, open-label, parallel-controlled, multicenter Phase III clinical study conducted in the entire population of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have previously received 1 to 4 lines of treatment. The study aims to compare the efficacy and safety of JSKN003 with the investigator's choice chemotherapy in this patient population.